KURA - Kura Oncology, Inc.
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura management is scheduled to participate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT on May 26, 2026.
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
Kura Oncology NASDAQ: KURA reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management's earnings call for the first quarter of 2026.
Kura Oncology (KURA) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.66 per share a year ago.
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase 3 results – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported first quarter 2026 financial results and provided a corporate update.
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Bank of America Securities 2026 Healthcare Conference. Kura management is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2026.
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.S. financial markets on Tuesday, May 12, 2026. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 133,750 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – – Regulatory Filing in Japan Planned Following Clinical Trial Completion –
Kura Oncology, Inc. remains a Buy, driven by ziftomenib's launch and promising combination trial data in AML. Ziftomenib's initial single-agent results are modest, but combination regimens (notably KOMET-007) show high response rates and deep remissions. KURA is well capitalized, with over $660 million in liquidity and a 2–2.5 year runway, minimizing near-term dilution risk.
Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.
Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Shares of Kura Oncology, Inc. (NASDAQ: KURA - Get Free Report) were up 9.7% during mid-day trading on Friday. The stock traded as high as $9.81 and last traded at $9.8030. Approximately 578,462 shares traded hands during trading, a decline of 60% from the average daily volume of 1,441,034 shares. The stock had previously closed
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy